Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study

Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study

Abstract Background While recent years have seen a revolution in the treatment of metastatic cutaneous melanoma, no treatment has yet been able to demonstrate any prolonged survival in metastatic uveal melanoma. Thus, metastatic uveal melanoma remains a disease with an urgent unmet medical need. Rep...

Full description

Bibliographic Details
Main Authors: Henrik Jespersen, Roger Olofsson Bagge, Gustav Ullenhag, Ana Carneiro, Hildur Helgadottir, Ingrid Ljuslinder, Max Levin, Charlotta All-Eriksson, Bengt Andersson, Ulrika Stierner, Lisa M. Nilsson, Jonas A. Nilsson, Lars Ny
Format: Article
Language:English
Published: BMC 2019-05-01
Series:BMC Cancer
Subjects:
Uveal melanoma
Metastatic
Immunotherapy
Programmed cell death 1 receptor
Pembrolizumab
Epigenetics
Online Access:http://link.springer.com/article/10.1186/s12885-019-5623-3

Internet

http://link.springer.com/article/10.1186/s12885-019-5623-3

Similar Items